Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 16Breast 3Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liposarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 42Carboplatin 24Cyclophosphamide 20Paclitaxel 19Nivolumab 17Cisplatin 15fludarabine 14Gemcitabine 12aldesleukin 10Docetaxel 10Bevacizumab 9Magnetic Resonance Spectroscopy 8Trastuzumab 7Specimen Handling 7Drug Therapy 7Pemetrexed 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Fluorouracil 6Cetuximab 6Blood Specimen Collection 6sargramostim 5pegfilgrastim 5avelumab 5Topotecan 5Taxes 5Irinotecan 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Letrozole × Thoracic × Clear all
NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡